Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|June 15, 2026
Linker-dependent variations in the tumoricidal activity of DZ-1-dihydroartemisinin conjugate formatsFarzaneh Vafaeinik, Sarah Helmueller, Yi Zhang, et al.
Future Oncology (London, England)|February 8, 2023
LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapyRobert J Motzer, Manuela Schmidinger, Masatoshi Eto, et al.
Cancer Research|December 2, 2010
Targeting STAT3 in adoptively transferred T cells promotes their in vivo expansion and antitumor effectsMaciej Kujawski, Chunyan Zhang, Andreas Herrmann, et al.
Frontiers in Bioscience (Elite Edition)|March 23, 2023
Targeting Glutamine Metabolism in Prostate CancerNeil Bhowmick, Edwin Posadas, Leigh Ellis, et al.
Molecular Therapy. Oncology|June 29, 2026
Tumoricidal efficacy of DZ-1 dye conjugated to dihydroartemisinin in patient-derived colorectal liver metastasis tumoroidsFarzaneh Vafaeinik, Badrinath Narayanasamy, Sarah Helmueller, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 5, 2005
Green tea extract modulates actin remodeling via Rho activity in an in vitro multistep carcinogenic modelQing-Yi Lu, Yu-Sheng Jin, Allan Pantuck, et al.
Cancer Research|September 16, 2010
Targeting Stat3 in the myeloid compartment drastically improves the in vivo antitumor functions of adoptively transferred T cellsAndreas Herrmann, Marcin Kortylewski, Maciej Kujawski, et al.
Oncology (Williston Park, N.Y.)|April 5, 2021
Integrating PARP Inhibitors Into Advanced Prostate Cancer TherapeuticsJun Gong, Edwin Posadas, Neil Bhowmick, et al.
Molecular Cancer|November 14, 2003
Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cellsKaren Riedl, Felicita Baratelli, Raj K Batra, et al.
The Journal of Gene Medicine|August 5, 2003
Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancerChristoph Rochlitz, Robert Figlin, Patrick Squiban, et al.
Pageof 6